This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Carvalho, J. G. Articles by Froholich, E. D. Search for Related Content PubMed PubMed Citation Articles by de Carvalho, J. G. Articles by Froholich, E. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Circulation, Vol 57, 373-378, Copyright © 1978 by American Heart Association

ARTICLES

Hemodynamic correlates of saralasin-induced arterial pressure changes

JG de Carvalho, FG Dunn, DC Kem, SG Chrysant and ED Froholich

Angiotensin antagonists have proved useful in elucidating the clinical role of the renin-angiotensin system; and their diagnostic and therapeutic efficacy in hypertension has been the subject of many reports but the hemodynamic effects remain unknown. Therefore, saralasin was infused intravenously (1.3 mg/min for 30 min) in 26 sodium-depleted patients with hypertension. Systemic hemodynamic alterations were determined before, during, and after infusion. On the basis of mean arterial pressure (MAP) changes, patients were classified as responders, nonresponders, or pressorresponders (MAP changes greater than or equal to 10 mm Hg). MAP fall in responders was achieved through reduced cardiac output and/or total peripheral resistance, with minimal or absent reflexive heart rate increase. In nonresponders, despite no change in MAP, output fell in parallel with stroke index and left ventricular ejection rate, In pressorresponders, saralasin increased vascular resistance. Thus, in addition to variable effects on vascular receptors, saralasin produced inhibitory cardiac effects either through altered venous return or inhibition of contractility.

This article has been cited by other articles:

				S. G. Chrysant Fixed Low-Dose Drug Combination for the Treatment of Hypertension Arch Fam Med, July 1, 1998; 7(4): 370 - 376. [Abstract] [Full Text] [PDF]

				E. D. Frohlich, M. H. Maxwell, L. Baer, H. Gavras, J. W. Hollifield, L. R. Krakoff, M. D. Lifschitz, A. Logan, E. Poutasse, and D. H. P. Streeten Use of Saralasin as a Diagnostic Test in Hypertension: Report of a Consensus Committee Arch Intern Med, August 1, 1982; 142(8): 1437 - 1440. [Abstract] [PDF]

				F. H. Messerli and E. D. Frohlich High Blood Pressure: A Side Effect of Drugs, Poisons, and Food Arch Intern Med, June 1, 1979; 139(6): 682 - 687. [Abstract] [PDF]